STOCKHOLM, 17e december 2021 – Lipidor AB (publ) (Nasdaq First North: LIPI) today announced that it has launched a preclinical program for a new drug candidate, AKP-08, focused on acne vulgaris (acne). The market for acne drugs is approximately 35 billion Swedish kronor per year, which, combined with the clinical needs of acne, makes it a very attractive indication for investment.
Acne vulgaris occurs in up to 96% of all teens and about 15% of them suffer from moderate or severe acne, which often causes major problems for the person who has it. Lipidor a, together with leading acne specialists in both Europe and the United States, have identified clinical needs that Lipidor spray treatment may improve and thus facilitate the daily life of large groups of patients.
The prescription acne drug market is valued at approximately 35 billion Swedish kronor and it is estimated to reach approximately 40 billion Swedish kronor by 2026 (according to Global Data 2018). The market is characterized by various segments, classes and categories of products where Lipidor the candidate product is included in what are called topical combination products.
“By focusing on well-established drug substances formulated in AKVANO®, Lipidor patented technology for the delivery of dermatological products, we can meet many clinical needs, create value and achieve good market share after launch, â€says Ola Holmlund, CEO of Lipidor. “We made a full selection of potential candidates and chose to prioritize AKP-08, which could potentially allow clear product differentiation and take large market share. Lipidor strategy is to enter into commercial agreements with leading pharmaceutical companies after completion of phase II or phase III studies. We believe there are very good opportunities to reach an agreement for the AKP-08 and will choose the timing carefully. “
AKP-08 development costs are funded from the company’s existing cash flow and license agreement revenues.
In 2021, Lipidor has successfully entered into licensing agreements with Menarini Group RELIFE skin regarding two drug candidates (AKP-01 and AKP-02) for psoriasis, and with Cannasure regarding medical cannabis. The clinical program for AKP-01 and AKP-02 is being conducted in collaboration with Cadila Pharmaceutics and the results of the ongoing phase III study for AKP-02 are expected in the first half of 2022.
Information
The information has been provided for publication through the office of the contact person below on 17e december 2021 at 8:30 am (CET).
For more information please contact
Ola Holmlund, CEO
Telephone: +46 (0) 72 50 70 369
Email: ola.holmlund@lipidor.se
Certified advisor
Bank Erik Penser AB
Telephone: +46 (0) 8 463 83 00
E-post: Certifiedadviser@penser.se
About AKVANO®
AKVANO® is an innovative waterless and sprayable technology for drug formulation and is particularly suitable for local application, for example on the skin. AKVANO® is composed of carefully selected lipids which, together with a volatile solvent, constitute carriers of selected active substances. By combining different lipids, AKVANO® can be optimized to achieve the desired function of the active components in the formulation. When applied to the skin, the solvent evaporates and a thin lipid layer forms on the skin surface for effective release of the active substance.
On Lipidor AB
Lipidor AB (www.lipidor.se) is Swedish, Stockholmresearch and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The Company develops topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulating proven pharmaceutical substances.
https://news.cision.com/lipidor/r/lipidor-expands-clinical-program–announces-investment-in-new-drug-development-project-against-acne-,c3473899
https://mb.cision.com/Main/17081/3473899/1511186.pdf
(c) Decision 2021. All rights reserved., source Press Releases – English
